Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of E7389, a Halichondrin B Analog, in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC), Who Progressed During or After Platinum-Based Doublet Chemotherapy Stratified for Prior Taxane Therapy

NCT00100932 is registered in ClinicalTrials.gov with Eisai Inc. as lead sponsor.

NCT NCT00100932
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00100932 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of E7389, a Halichondrin B Analog, in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC), Who Progressed During or After Platinum-Based Doublet Chemotherapy Stratified for Prior Taxane Therapy
Lead sponsor
Eisai Inc.
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2004
Completion date
Not reported
Enrollment
106 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

non-small-cell lung carcinoma